Eyal C. Attar - 03 Jun 2022 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
SVP, Chief Medical Officer, Director
Signature
/s/ Scott M. Coiante, attorney-in-fact
Issuer symbol
APRE
Transactions as of
03 Jun 2022
Net transactions value
-$26,297
Form type
4
Filing time
07 Jun 2022, 17:00:32 UTC
Previous filing
14 Mar 2022
Next filing
12 Oct 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APRE Common Stock Tax liability $26,297 -32,667 -36% $0.8050* 57,233 03 Jun 2022 Direct F1
holding APRE Common Stock 172 03 Jun 2022 By adult child F2
holding APRE Common Stock 159 03 Jun 2022 By adult child F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 89,900 restricted stock units.
F2 The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.